A randomised, double-blind, placebo-controlled study, in COPD patients with and without a confirmed respiratory virus infection assessing anti-viral biomarker responses of inhaled SNG001 compared to placebo

Trial Profile

A randomised, double-blind, placebo-controlled study, in COPD patients with and without a confirmed respiratory virus infection assessing anti-viral biomarker responses of inhaled SNG001 compared to placebo

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Synairgen
  • Most Recent Events

    • 28 Jun 2018 According to a Synairgen media release, the second part of this study is scheduled to cover the 2018/19 winter cold virus season and aims to enrol 80 patients with confirmed respiratory viruses.
    • 28 Jun 2018 Positive biomarker results presented in a Synairgen media release.
    • 26 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top